Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416358
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
Sponsor:
AlaMab Therapeutics Shanghai Inc
Organization:
AlaMab Therapeutics Shanghai Inc
Study Overview
Official Title:
A Phase IIa Multi-center Single-Arm Open-Label Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bone metastasis is a common disease of advanced tumors It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system The incidence of bone metastasis in breast and prostate cancer is as high as 65-75 Bone metastasis of malignant tumors often leads to severe bone lesions including bone pain pathological fractures spinal cord compression hypercalcemia and other bone-related events SRE SRE caused by bone metastasis of tumors can greatly reduce the quality of life of tumor patients In severe cases it can lead to rapid deterioration of the condition or even death which greatly affects the extension of the patients survival period ALMB-0168 is designed to activate Cx43 hemichannels which release key anti-cancer factors such as ATP into the extracellular environment In several mouse models of breast cancer bone metastasis and orthotopic osteosarcoma ALMB-0168 dose-dependently inhibited tumor growth and was able to extend the lifespan of tumor-bearing animals indicating its potential as a therapeutic drug for malignant bone tumors Clinical research data from China and Australia show that ALMB-0168 is safe and initially effective in patients with bone metastasis and osteosarcoma
Detailed Description:
Avoid duplicating information that will be entered elsewhere such as Eligibility Criteria or Outcome Measures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None